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Abstract: In subjects at risk for psychosis, the studies on gray matter volume (GMV) predominantly
reported volume loss compared with healthy controls (CON). However, other important morphological
measurements such as cortical surface area (CSA) and cortical thickness (CT) were not systematically
compared. So far, samples mostly comprised subjects at genetic risk or at clinical risk fulfilling an ultra-
high risk (UHR) criterion. No studies comparing UHR subjects with at-risk subjects showing only basic
symptoms (BS) investigated the differences in CSA or CT. Therefore, we aimed to unravel the contribution
of the 2 morphometrical measures constituting the cortical volume (CV) and to test whether these groups
inhere different morphometric features. We conducted a surface-based morphometric analysis in 34 CON,
46 BS, and 39 UHR to examine between-group differences in CV, CSA, and CT vertex-wise across the
whole cortex. Compared with BS and CON, UHR individuals presented increased CV in frontal and
parietal regions, which was driven by larger CSA. These groups did not differ in CT. Yet, at-risk subjects
who later developed schizophrenia showed thinning in the occipital cortex. Furthermore, BS presented
increased CSA compared with CON. Our results suggest that volumetric differences in UHR subjects are
driven by CSA while CV loss in converters seems to be based on cortical thinning. We attribute the larger
CSA in UHR to aberrant pruning representing a vulnerability to develop psychotic symptoms reflected
in different levels of vulnerability for BS and UHR, and cortical thinning to a presumably stress-related
cortical decomposition.
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In	 subjects	 at	 risk	 for	 psychosis,	 studies	 on	 gray	 matter	 volume	 (GMV)	 predominantly	
reported	 volume	 loss	 compared	 to	 healthy	 controls	 (CON).	 However,	 other	 important	
morphological	 measurements	 such	 as	 cortical	 surface	 area	 (CSA)	 and	 cortical	 thickness	
(CT)	 were	 not	 systematically	 compared.	 So	 far,	 samples	 mostly	 comprised	 subjects	 at	
genetic	 risk	 or	 at	 clinical	 risk	 fulfilling	 an	 ultra-high	 risk	 (UHR)	 criterion.	 No	 studies	
comparing	 UHR	 subjects	 with	 at-risk	 subjects	 showing	 only	 basic	 symptoms	 (BS)	
investigated	differences	 in	CSA	or	CT.	Therefore,	we	aimed	 to	unravel	 the	contribution	of	
the	 two	morphometrical	measures	 constituting	 the	CV,	 and	 to	 test	whether	 these	 groups	
inhere	different	morphometric	features.	
We	 conducted	 a	 surface-based	morphometric	 analysis	 in	 34	 CON,	 46	 BS,	 and	 39	 UHR	 to	
examine	between-group	differences	in	CV,	CSA,	and	CT	vertex-wise	across	the	whole	cortex.			
Compared	to	BS	and	CON,	UHR	individuals	presented	increased	CV	in	 frontal	and	parietal	
regions,	 which	 was	 driven	 by	 larger	 CSA.	 These	 groups	 did	 not	 differ	 in	 CT.	 Yet,	 at-risk	
subjects	 who	 later	 developed	 schizophrenia	 showed	 thinning	 in	 the	 occipital	 cortex.	
Further,	BS	presented	increased	CSA	compared	to	CON.	
Our	results	suggest	that	volumetric	differences	in	UHR	subjects	are	driven	by	CSA	while	CV	
loss	 in	 converters	 seems	 to	be	based	on	 cortical	 thinning.	We	attribute	 the	 larger	CSA	 in	
UHR	 to	 aberrant	 pruning	 representing	 a	 vulnerability	 to	 develop	 psychotic	 symptoms	





There	 is	 ample	 evidence	 for	 morphometric	 brain	 alterations	 in	 schizophrenia,	 most	
consistently	 in	 terms	 of	 decreased	 gray	matter	 volume	 (GMV)	 or	 gray	matter	 density1–3.	
Studies	show	that	already	subjects	at	risk	for	psychosis	present	reductions	of	cortical	GMV	
relative	 to	 healthy	 controls	 (CON),	 similarly	 located	 but	 less	 pronounced	 than	 in	




criteria	 are	 used	 to	 diagnose	 the	 clinical	 risk:	 the	 basic	 symptoms	 (BS)	 criteria	 and	 the	
ultra-high	 risk	 (UHR)	 criteria.	 The	 BS	 consist	 of	 subtle,	 subclinical,	 self-experienced	
disturbances,	 that	 are	 experienced	 as	 dysfunctional9,10,	 subsumed	 in	 two	 BS	 criteria,	 i.e.	
cognitive-perceptive	BS	(COPER)	and	cognitive-disturbances	(COGDIS).	This	approach	was	
developed	 to	detect	 the	 risk	 for	psychosis	 as	 early	 as	possible	 in	 the	development	 of	 the	
illness,	ideally	before	functional	impairments	appeared11.	In	contrast,	the	UHR	criteria	were	
originally	developed	with	the	explicit	aim	of	detecting	an	imminent	risk	for	transition	into	a	
manifest	 psychosis	 within	 the	 next	 twelve	 months.	 An	 UHR	 criterion	 is	 met	 by	 either	
presenting	 brief,	 limited,	 intermittent	 psychotic	 symptoms	 (BLIPS),	 attenuated	 psychotic	
symptoms	 (APS),	 or	 alternatively	meeting	 the	 state-trait	 criterion12,13.	 It	 is	 assumed	 that	
basic	symptoms	arise	earlier	in	the	course	of	the	disease14.	Additional	APS	may	occur	in	the	
further	 course,	 and	 it	 is	 also	being	discussed	whether	APS	occur	 in	 response	 to	 the	basic	
symptoms15.	




frontal	 and	 temporal	 regions19,20.	 When	 CT	 in	 clinical	 risk	 subjects	 was	 investigated,	
thinning	 in	 temporal,	 frontal,	 parietal,	 and	 occipital	 regions	 was	 found6.	 Other	 studies	
reported	negative	findings	in	UHR21–25	or	cortical	thickening	in	clinical8	and	genetic26	high-
risk	 subjects.	 Further,	 Prasad	 et	 al.27	 found	 decreased	 CSA	 in	 a	 genetic	 high-risk	 sample	
compared	 to	 CON.	However,	 it	 should	 be	 considered	 that	 some	 studies	 included	 subjects	
only	on	the	basis	of	the	genetic	risk	without	functional	decline,	which	is	associated	with	a	
rather	low	conversion	rate.	
Since	 most	 imaging	 studies	 on	 at-risk	 subjects	 are	 based	 on	 genetic	 high-risk	 or	 UHR	
samples,	only	little	is	known	about	at-risk	subjects	suffering	from	BS.	Nevertheless,	a	voxel-
based	 morphometry	 (VBM)	 study	 yielded	 that	 subjects	 suffering	 from	 BS	 showed	 GMV	
reductions	 in	temporolimbic	regions	relative	to	CON28.	Subjects	meeting	an	UHR	criterion	
additionally	 showed	reduced	GMV	 in	prefrontal	 areas,	 enabling	 to	distinguish	 the	 two	at-
risk	groups28.	The	pattern	of	these	differential	neuroanatomical	properties	associated	with	




well	 as	 the	 majority	 of	 morphometric	 studies	 in	 subjects	 at	 clinical	 risk	 are	 based	 on	
volumetric	measurements.	Since	CV	is	constituted	by	CT	and	CSA31,	loss	of	GMV	could	be	a	
result	 of	 cortical	 thinning,	 or	 reduced	 CSA,	 or	 a	 combination	 of	 both.	Hence,	 any	 cortical	
thinning	 in	 combination	with	 extended	 CSA	 in	 the	 same	 region,	 or	 vice	 versa,	 cannot	 be	
detected	 by	 analyzing	 the	 GMV.	 Furthermore,	 as	 CSA	 and	 CT	 are	 related	 to	 different	
genetic32,33	 and	 different	 developmental	 trajectories31,	 the	 analysis	 of	 both	 properties	
reveals	 distinct	 information	 and	might	 shed	 light	 on	 aberrant	 processes	 involved	 in	 the	
pathogenesis.	 Reduced	 CT	 together	with	 normal	 CSA	 –	 as	 reported	 in	 neurodegenerative	
diseases34,35 –	 would	 refer	 to	 neurodegenerative	 pathogenetic	 models36	 in	 contrary	 to	
neurodevelopmental	models	of	pathogenesis37.	
	To	 the	 best	 of	 our	 knowledge,	 no	 publication	 investigated	measures	 of	 CV,	 CT,	 and	 CSA	
comparing	 BS,	 UHR,	 and	 CON	 so	 far.	 Therefore,	 we	 analyzed	 CV,	 CT,	 and	 CSA	 in	 these	
populations	 and	 tested	 whether	 at-risk	 subjects	 fulfilling	 UHR	 criteria	 present	
morphometric	differences	compared	to	at-risk	subjects	meeting	only	BS	criteria.	Based	on	
the	 results	 reported	by	Koutsouleris	 et	 al.28,	we	hypothesized	 that	 at-risk	 subjects	would	
show	reductions	of	GMV	relative	to	CON,	specifically	the	UHR	group	more	pronounced	than	
the	 BS	 group.	 Further,	 as	 GMV	 loss	 in	 schizophrenia	 was	 found	 to	 be	 based	 on	 cortical	







consent	 form,	 after	 they	 were	 informed	 about	 the	 study40.	 After	 excluding	 MRI	 data	 of	
inadequate	quality	(e.g.	due	to	artifacts)	and	balancing	the	groups	regarding	age	(mean±sd:	
22.11±4.17,	 range:	16-35),	 sex,	 handedness,	 and	 IQ,	119	 individuals	were	 included	 in	 the	
analyses:	46	subjects	showing	BS	(3	with	transition	to	schizophrenia),	39	subjects	fulfilling	
an	 UHR	 criterion	 (7	 with	 transition)	 and	 34	 CON.	 Since	 the	 majority	 of	 UHR	 subjects	
(35/39)	 also	met	BS	 criteria	 (supplementary	 text	 S1.4),	 there	 is	 a	 large	 overlap	 between	
UHR	and	BS	which	should	be	highlighted.	Subsets	of	this	sample	(76	subjects)	of	which	fMRI	
data	were	available	were	part	of	our	previous	fMRI	studies41,42.		
The	 adult10	 respectively	 the	 children-youth43	 version	 of	 the	 Schizophrenia	 Proneness	
Instrument	was	used	to	assess	basic	symptoms.	Persons	included	in	the	BS	group	presented	
either	at	least	one	out	of	ten	cognitive-perceptive	(COPER)	symptoms	or	at	least	two	of	nine	
cognitive	 disturbances	 (COGDIS).	 UHR	 subjects	 reported	 at	 least	 one	 APS	 or	 one	 BLIPS,	
assessed	 by	 the	 Structured	 Interview	 for	 Prodromal	 Syndromes	 (SIPS)13	 (see	
supplementary	 text	 S1.2	 for	 more	 details).	 Subjects	 fulfilling	 only	 the	 state-trait	 criteria	
were	not	 included	because	they	did	not	present	psychotic	symptoms	(supplementary	text	
S1.3).	 In	 total,	 8	 BS	 and	 12	 UHR	 subjects	 were	 being	 treated	 with	 second-generation	
(atypical)	antipsychotic	drugs.	Within	a	span	of	3	years	(mean=12.2	months),	10	individuals	




Neuropsychiatric	 Interview44	 was	 conducted.	 Exclusion	 criteria	 for	 all	 participants	 were	
contraindications	against	MRI,	pregnancy,	history	of	neurological	disease,	and	drug/alcohol	
dependence.	Further,	 subjects	holding	organic	brain	anomalies	 (supplementary	 text	S1.1)	
were	excluded	from	the	study	(n=14),	as	verified	by	an	experienced	neuroradiologist.	
In	 order	 to	 balance	 the	 three	 groups	 regarding	 IQ	 and	 handedness	 (Table	 1),	 levels	 of	
intelligence	 were	 estimated45	 in	 adults	 with	 a	 German	 test	 for	 word	 recognition	
(Mehrfachwahl	Wortschatz	Test,	Version	B;	MWT-B)46	and	in	adolescent	subjects	(age	<20)	







structural	 images	 of	 the	 whole	 brain.	 Data	 were	 obtained	 on	 a	 Philips	 Achieva	 TX	 3-T	
whole-body	 MR	 unit,	 using	 an	 8-channel	 head	 coil	 and	 a	 fast	 field	 echo	 pulse	 sequence	
(repetition	 time,	 TR=8.3ms,	 echo	 time,	 TE=3.8ms,	 flip-angle	 8	 degree,	 field	 of	 view,	 FOV	
240x240mm2,	 voxel	 size	 1x1x1mm3	 (reconstructed:	 0.94x0.94x1mm3),	 160	 contiguous	
slices.	 Images	with	 obvious	 artifacts	 (e.g.,	 caused	by	 head	motion	 or	 dental	 braces)	were	
excluded	from	the	study	(n=4).	All	datasets	were	processed	on	the	same	workstation	using	
FreeSurfer	 version	 5.3.0	 (http://surfer.nmr.mgh.harvard.edu).	 The	 automated	 processing	
stream	enables	to	extract	reliable	estimates	of	cortical	anatomic	measures.	The	procedure	
included	 several	 steps:	 intensity	 normalization,	 skull-stripping,	 Talairach	 transformation,	
and	 atlas-based	 assignment	 of	 neuro-anatomical	 labels,	 as	 previously	 described49.	 The	
generated	 models	 of	 the	 cortical	 surfaces,	 defined	 by	 the	 white/gray	 boundary	 and	
gray/cerebrospinal	 fluid	 boundary,	 allowed	 to	 calculate	 CT	 (representing	 the	 closest	
distance	 between	 white	 and	 pial	 surfaces),	 CSA	 as	 well	 as	 the	 product	 of	 CT	 and	 CSA	
(representing	CV).	These	morphometric	features	were	calculated	at	each	vertex	across	the	
whole	 cortex.	 Generated	 models	 were	 visually	 inspected	 for	 each	 subject,	 and	 data	 was	
excluded	 from	 the	 study	 in	 case	 the	visual	 inspection	 revealed	errors	 (n=9).	 Finally,	 data	




In	 order	 to	 assure	 a	balanced	distribution	between	groups	with	 respect	 to	 age	 and	 IQ	 as	
well	 as	 sex	 and	 handedness,	we	 performed	 statistical	 tests	 using	 the	R	 3.2.3	 software	 (R	
Core	 Team,	 2015):	 One-way	 analyses	 of	 variances	 (ANOVAs)	 or	 chi-square	 tests	 were	
applied.	 In	case	Shapiro-Wilk	test	 for	normality	revealed	that	 the	dependent	variable	was	
not	normally	distributed,	Kruskal-Wallis	 test	 instead	of	ANOVA	was	performed.	The	same	






did	 not	 include	 these	 variables.	 F-tests	 were	 performed	 to	 identify	 whether	 there	 are	
differences	between	any	of	the	three	groups.	In	case	of	a	significant	main	effect	post-hoc	T-
tests	 comparing	 BS	 versus	 UHR,	 BS	 versus	 CON,	 and	 UHR	 versus	 CON	 were	 conducted	
separately.	 We	 further	 investigated	 subgroups	 of	 at-risk	 groups,	 defined	 by	 the	 clinical	
outcome,	i.e.	10	at-risk	subjects	with	transition	(RISK-T)	to	schizophrenia	(F20	according	to	
ICD-1050)	 versus	 those	 without	 transition	 (RISK-NT).	 Subjects	 with	 transition	 to	 other	
diseases	than	schizophrenia	were	not	included	in	this	additional	analysis,	predominantly	to	
increase	 the	 homogeneity	 of	 the	 RISK-T	 sample	 (supplementary	 text	 S1.5.1).	 Further,	
Spearman’s	 correlation	 was	 used	 to	 examine	 the	 association	 between	 morphometric	
measures	 and	 symptoms	 (SIPS	 positive	 score,	 COPER	 and	 COGDIS	 sum	 scores,	 Tables	
S2.3.1-S2.3.3,	Fig.	S2.6.1-S2.6.4).		




Some	 at-risk	 subjects	 were	 treated	 with	 antipsychotic	 medication	 (Table	 1),	 which	 are	
known	to	inhere	the	potential	to	induce	morphological	changes	on	gray	matter51.	We	thus	





The	 three	 groups	 were	 balanced	 regarding	 age	 (p=.5111),	 sex	 (p=.2789),	 handedness	
(p=.2659)	 and	 IQ	 (p=.1034).	 Significant	 between-group	differences	were	 found	 in	COPER	
sum	 score	 (p<.0216),	 SIPS	positive	 score	 (p<.0001),	 SIPS	disorganization	 (p<.0001),	 SIPS	
general	(p<.0197)	and	global	functioning	(GAF,	p=.0087)	between	the	BS	and	UHR	groups.	










showed	 greater	 GMV	 than	 BS	 in	 the	 left	 lateral	 orbitofrontal	 (p=.0001,	 Monte	 Carlo	






in	 UHR	 compared	 to	 BS	 in	 a	 left	 lateral	 orbitofrontal	 region	 (p=.0007,	 Monte	 Carlo	
simulation)	 as	 well	 as	 in	 the	 right	 posterior	 cingulate	 cortex	 (p=.0107,	 Monte	 Carlo	
simulation)	as	shown	in	Fig.	1.	UHR	also	demonstrated	larger	CSA	when	compared	to	CON	
in	 left	 orbitofrontal	 and	 lateral	 occipital	 cortex	 (p=.0469,	 Monte	 Carlo	 simulation	 and	













Monte	 Carlo	 simulation)	when	 compared	 to	 RISK-NT	 (Fig.	 2,	 Table	 S2.1.3).	 Compared	 to	
CON,	 RISK-T	 differed	 in	 CT	 in	 the	 left	 lateral	 occipital	 cortex	 (p=.0018,	 Monte	 Carlo	











The	 clusters	 showing	 increased	CSA	 in	UHR	are	not	 significantly	 correlated	with	positive	
symptoms,	 neither	 the	 cluster	with	 cortical	 thinning	 in	 the	 left	 lateral	 occipital	 cortex	 in	





criteria	 and	 to	 test	whether	 these	 two	 groups	 can	 be	 differentiated	 from	 each	 other	 and	
from	CON	 in	 regard	 to	 their	morphometric	measures.	We	observed	 increased	CV	 in	UHR	
subjects	in	the	cingulate	cortex	and	in	frontal	regions	relative	to	BS	and	in	frontal,	parietal	
and	 occipital	 regions	 compared	 to	 CON.	 These	 differences	were	 produced	 by	 larger	 CSA.	
Further,	 BS	 showed	 increased	 CSA	 in	 a	 left	 temporal	 area	 when	 compared	 to	 CON.	 No	
alterations	 in	 CT	 were	 found	 in	 the	 UHR	 and	 BS	 groups	 but	 RISK-T	 presented	 cortical	
thinning	in	the	lateral	occipital	cortex	at	baseline	relative	to	RISK-NT.	
	
According	 to	 the	 radial	 unit	 hypothesis52,	 CSA	 is	 determined	 by	 the	 number	 of	 cortical	
columns,	 whereas	 CT	 is	 based	 on	 the	 number	 of	 neurons	 within	 a	 column52,53.	 The	 two	
components	 are	 driven	 by	 different	 genetic	 mechanisms32,33,	 and	 also	 different	
developmental	influences.	A	study	investigating	the	cortical	development	in	early	childhood	
reported	that	CT	is	developed	earlier	than	CSA:	By	age	two,	CT	is	97%	of	adult	values,	CSA	
only	 69%.	 The	 authors	 concluded	 that	 cortical	 growth	 after	 age	 1	 is	 mainly	 induced	 by	
increases	in	CSA54.	
The	 CV	 differences	 between	 UHR	 subjects	 and	 BS/CON	 in	 our	 sample	 were	 driven	 by	
differences	 in	 CSA.	 Hence,	 CV	 differences	 driven	 by	 CSA	 between	 UHR	 and	 CON	 might	
indicate	that	developmental	processes	which	determine	cortical	growth	are	affected	in	UHR	
subjects.	These	alterations	might	occur	either	in	cell	migration55	early	in	development	(pre-
/perinatal),	 or	 in	 later	 processes	 which	 normally	 reduce	 CSA	 in	 development	 (i.e.,	
pruning)56.	 We	 suggest	 that	 later	 processes,	 which	 are	 supposed	 to	 reduce	 the	 surface,	





cause	 changes	 in	 perceptual	 or	 reinforcement	 learning	 potentially	 resulting	 in	
neurocognitive	 aberrations,	 delusions	 and	 hallucinations57,58.	 We	 suppose	 that	 aberrant	
synaptic	 plasticity	 might	 lead	 to	 changes	 in	 pruning	 due	 to	 strengthening	 of	 “atypical”	
synaptic	connections	which	will	consequently	be	reflected	 in	 increased	regional	CSA.	This	
might	explain	why	 the	orbitofrontal	 cortex,	 a	 region	 involved	 in	 reinforcement	 learning59	
showed	increased	CSA	in	UHR.		
Therefore,	we	suggest	that	increased	CSA	in	UHR	subjects	might	reflect	aberrant	or	delayed	
pruning.	 It	 is	 also	 conceivable,	 that	 increased	CSA	occurs	due	 to	 insufficient	 (or	delayed)	





Alternatively,	 the	 increase	of	CSA	might	be	caused	by	cortical	 reorganization:	Taking	 into	
consideration	 that	 UHR-symptoms	 are	 thought	 to	 develop	 from	 basic	 symptoms63	 or	
eventually	arise	in	response	to	them,	and	the	majority	of	UHR	subjects	in	our	sample	also	
presents	basic	symptoms,	the	increased	CSA	might	reflect	these	compensational	processes,	
also	 discussed	 as	 indicator	 of	 resilience60.	 Yet,	 CSA	 increases	 did	 not	 correlate	 with	
symptoms.	This	might	be	a	hint	 that	 these	changes	are	related	to	 the	development	rather	
than	to	a	putative	compensation8,60.		
	
Regarding	CT	differences,	 our	negative	 finding	 is	 in	 line	with	 studies	 showing	no	or	 only	
subtle	 morphometric	 differences	 in	 at-risk	 subjects22,24.	 Yet,	 cortical	 thinning	 without	
differences	 in	 CV	 and	 CSA	 has	 been	 reported	 in	 converters64.	 Accordingly,	 our	 analyses	
revealed	 occipital	 cortices	 to	 be	 thinner	 in	 converters.	 Hence,	 transition	 to	 psychosis	
appears	 to	 be	 associated	 with	 decreased	 CT.	 This	 assumption	 is	 in	 line	 with	 studies	
concluding	 that	 CV	 loss	 in	 schizophrenia	 patients	 is	 driven	 by	 cortical	 thinning38,39.	 In	
contrast,	Bois	et	al.65	 found	that	in	their	genetic	at-risk	sample	increased	CSA	is	related	to	
the	 transition	 while	 cortical	 thinning	 was	 not	 associated	 with	 the	 subsequent	 clinical	
outcome.	 Here,	 the	 questions	 about	 the	 time	 point	 of	 appearance	 and	 the	 causes	 of	
alterations	in	CT	arise.	One	study	revealed	differences	very	early	in	development:	In	their	
preliminary	study,	Li	 et	al.66	 found	smaller	 (along	with	 increased)	CT	 in	genetic	high-risk	
neonates,	indicating	that	differences	in	CT	in	the	sense	of	a	reduced	cortical	growth	might	
arise	 already	 around	 time	 birth.	 Yet,	 these	 preliminary	 results	 originate	 from	 region	 of	
interest	 (ROI)-based	 analyses,	 most	 of	 the	 differences	 were	 only	 detected	 without	





et	 al.24	 found	 the	 rate	 of	 prefrontal	 cortical	 thinning	 to	 be	 predicted	 by	 proinflammatory	
markers	 at	 baseline	 with	 stronger	 association	 in	 subjects	 who	 subsequently	 developed	
psychosis.	 Remarkably,	 neither	 the	 levels	 of	 these	markers	 nor	 CT	 at	 baseline	 did	 differ	
between	groups.	It	is	still	not	known	whether	these	microglial	alterations	are	causative	or	
not.	 Cortical	 thinning	 (also	 the	 possibly	 inflammatory	 processes)	 could	 represent	 a	
consequence	of	stress,	caused	by	increasing	and	persisting	symptoms.	It	is	well	established	
that	 repeated	 or	 chronic	 stress	 provokes	morphological	 changes	 in	 the	 brain,	 e.g.	 in	 the	
hippocampus	but	 also	 in	prefrontal	 cortical	 areas69,	 notably	 structures	demonstrating	CV	
loss	and	cortical	thinning	in	schizophrenia	as	well	as	in	at-risk	subjects4,70.	Hence,	cortical	
thinning	might	be	rather	related	to	stress	than	to	the	transition	itself.		
Our	 findings	 indicate	 that	 CV	 differences	 driven	 by	 CSA	 might	 be	 caused	 by	 aberrant	
developmental	processes	(presumably	deficient/delayed	pruning)	and	could	represent	the	
basis	 for	 the	 increased	 vulnerability	 to	 develop	 psychotic	 symptoms.	 In	 contrast,	 cortical	
thinning,	probably	related	to	pubertal	stressors	and	stress	provoked	by	arising	symptoms,	
might	 drive	 the	 volume	 loss	 detected	 in	 at-risk	 samples	 with	 a	 high	 percentage	 of	




the	 literature:	 As	morphometric	 differences	 increase	 from	 the	 at-risk	 state	 to	 psychosis,	
different	 transition	 rates	 are	 likely	 to	 be	 associated	 with	 differently	 pronounced	









When	 interpreting	 our	 results,	 it	 has	 to	 be	 taken	 into	 account	 that	 some	 at-risk	 subjects	
were	 treated	 with	 antipsychotic	 medication	 (Table	 1),	 which	 are	 known	 to	 inhere	 the	
potential	 to	 induce	 morphological	 changes	 on	 gray	 matter51,72.	 We	 thus	 performed	
additional	analyses	controlling	for	CPZ	equivalents.	The	results	(Fig.	S2.2.1/S2.2.2)	did	not	
dissent	 substantially	 from	 the	 presented	 results	 without	 including	 CPZ	 equivalents	 as	 a	






contrast,	CV	 loss	 in	 converters	 is	 related	 to	 cortical	 thinning.	We	conclude	 that	 increased	
CSA	might	result	 from	aberrant	or	delayed	pruning	owed	to	a	neurodevelopmental	delay.	
We	consider	the	increased	CSA	to	represent	a	predisposition	for	psychotic	symptoms	more	
pronounced	 in	 UHR	 than	 in	 subjects	 with	 only	 BS	 reflecting	 different	 risk-levels	 for	
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Morphometric	 differences	 between	 the	 three	 study	 groups.	 The	 three	 post-hoc	 tests	
comprise	the	comparisons	of	at-risk	subjects	showing	only	basic	symptoms	(BS),	subjects	at	
ultra-high	 risk	 (UHR),	 and	 healthy	 controls	 (CON).	 Blue	 highlighting	 indicates	 areas	with	




Morphometric	 differences	 between	 at-risk	 subjects	 who	 later	 developed	 psychosis	
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S1 SUPPLEMENTARY METHODS AND PARTICIPANTS
S1.1 Exclusion due to organic brain anomalies
All MRI data were assessed by an experienced neuroradiologist. Each subject had previously given his/her consent for
this clinical assessment. The neuroradiologist had no information about the group allocation of the subjects. The decision
he made about exclusion due to brain changes was therefore independent of the group assignment.
These subjects stemmed from the following groups and have been excluded due to the following organic brain anomalies:
CON group: Cavernoma (1 subject), arachnoidal cyst (1), lesions (2), increased ventricles (2)
BS group: Pineal cyst (1), perivascular lesions (1), multiple subcortical lesions (2)
UHR group: Demyelination (2), vascular lesions (1), perivascular lesions (1)
S1.2 Clinical assessments
All investigators who conducted psychopathological assessments received extensive training and were either psychologists
or psychiatrists. In subjects at risk (BS and UHR groups), psychopathological data was gathered with the Schizophrenia
Proneness Instrument-adult [1], and -child and youth Version (SPI-CY, SPI-A) [1; 2], the Structured Interview for Prodro-
mal Syndromes (SIPS) [3; 4], the Positive and Negative Syndrome Scale (PANSS) [5], Hypomania Checklist (HCL-32)
[6], Calgary Depression Scale [7], Hamilton Depression Scale (HAMD) [8], and Beck Anxiety Inventory (BAI) [9].
Subjects belonging to the CON group were assessed using the the Mini-International Neuropsychiatric Interview [10],
those CON subjects who showed a preceding or ongoing psychiatric illness were excluded from the study. Since the
control group was not explicitly examined for psychosis risk criteria, it cannot be completely excluded that individual
persons from the control group also met the risk criteria. However, the probability is to be considered low, since the
control subjects were not persons seeking help and all those with current or past substance use have been excluded.
S1.3 UHR group: state-trait criteria
According to McGlashan et al. [11], the state-trait criteria (genetic risk and deterioration syndrome, GRD) are one of
the UHR approaches. As subjects fulfilling only the state-trait criteria are not presenting psychotic symptoms, a reviewer
suggested to exclude these subjects. Hence, four subjects who only met the state-trait criteria were excluded from the
analyses. Consequently, each UHR subject in this study presented psychotic symptoms as characterized in APS or BLIPS.
However, the results with and without these four subjects fulfilling only the state-trait criteria were almost the same.
S1.4 Clinical criteria met in BS and UHR groups
BS group
46 subjects whereof ...
• 31 subjects fulfill COPER & COGDIS
• 14 subjects fulfill COPER
• 1 subject fulfills COGDIS
UHR group
39 subjects whereof ...
• 39 fulfill UHR criteria:
– 1 subject fulfills APS & BLIPS
– 35 subjects fulfill APS
– 3 subjects fulfill BLIPS
• 35 (additionally) fulfill BS criteria:
– 24 subjects COPER & COGDIS
– 8 subjects COPER
– 3 subjects COGDIS
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S1.5 Transition (RISK-T group)
S1.5.1 Exclusion due to transition into F23 and Bipolar I disorder
As indicated in Table 1 of the article, four subjects of the RISK groups (BS and UHR) subsequently developed a frank
psychotic disorder different from schizophrenia (according to ICD-10 [12]):
BS group: 2 subjects developed F23 (acute and transient psychotic disorders)
UHR group: 1 subject developed F23
1 subject developed Bipolar I disorder
Since the prediction of the transition into a manifest schizophrenic disease according to ICD-10 [12] was defined as target
parameter already during the planning of our ZInEP study [13], our aim was to identify those individuals who have a
severe course of the disease and a high symptom burden. Although the three transitions to F23 had a severe symptom
burden over a transient period, their symptoms were completely remitted after a few weeks as required by the ICD-10
[12] criteria. Therefore, we decided not to include the three transitions to F23 as converters in the analyses.
Regarding the transition to bipolar disorder: There is evidence for neurobiological differences between schizophrenia
and bipolar disorder found on the structural [14] and the functional level [15] and also prior to the onset [16] (although
this study is investigating subjects with a familial risk of psychosis). Hence, we decided to restrict the analysis related
to transition to schizophrenia aiming to increase the homogeneity of this subsample (RISK-T). These four subjects with
transition to non-schizophrenia psychosis were not included in the RISK-NT group either because these subjects cannot
be considered resilient due to their transition to a mental disease.
Consequently, the RISK-T group comprised only subjects with transition to schizophrenia according to ICD-10 [12]
criteria.
S1.5.2 Time to transition (RISK-T)
Time (in months) to transition into schizophrenia for the ten RISK-T subjects: 2, 3, 4, 6, 7, 9, 13, 17, 28, 33


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































S2.2 Additional analysis: Morphological differences when controlling for chlorpromazine (CPZ)
equivalents
Because some of the subjects in the at risk state were treated with antipsychotics (Table 1), we wanted to test whether
our results are influenced by this treatment. Therefore, we included calculated chlorpromazine (CPZ) equivalents as a
nuisance variable. This additional analysis revealed that the reported results were not driven by antipsychotic treatments.




































Figure S2.2.1. Differences in cortical volume and surface area when controlling
for chlorpromazine (CPZ) equivalents in subjects presenting basic symptoms
(BS) compared to individuals at ultra-high risk (UHR). Colored highlights show
areas of significant different cortical volume and cortical surface area (p < .05, two-tailed,
corrected for multiple comparisons); red would indicate a smaller volume/surface area in UHR




Figure S2.2.2: Differences in RISK-T vs. RISK-NT when controlling for chlorpromazine (CPZ) equivalents





















Figure S2.2.2. Differences in cortical thickness when controlling for chlorpro-
mazine (CPZ) equivalents in at-risk subjects grouped according to their clinical
outcome, i. e. subjects who later developed psychosis (RISK-T) vs. those who
did not (RISK-NT). Only one cluster survived the correction for multiple comparisons pic-
tured on the lateral (left) and the caudal/inferior (right) view of the left hemisphere. Colored
highlights show areas of significant different cortical thickness (p < .05, two-tailed, corrected
for multiple comparisons); red indicates increased values in the first group of the comparison,
while blue shows regions with increased values in the second group of the comparison.
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S2.3 Additional analysis: Correlation with symptoms
Correlations were tested between the morphometric values (cortical surface area or cortical thickness, respectively) and
the symptoms (SIPS positive, COPER sum score, COGDIS sum score). The morphometric values stem from significant
clusters revealed by comparing the group regarding CSA (or CT, respectively).
Table S2.3.1: Correlation between clusters with morphometric differences and positive symptoms
Cluster Correlation Coefficient Rho P
Correlation in UHR
Surface Area Left Orbitofrontal (CSA difference BS vs. UHR) 0.21 .1929
Surface Area Right Posterior Cingulate (CSA difference BS vs. UHR) 0.08 .6124
Surface Area Left Orbitofrontal (CSA difference CON vs. UHR) 0.23 .1647
Surface Area Left Lateral Occipital (CSA difference CON vs. UHR) 0.07 .6578
Surface Area Right Superior Parietal (CSA difference CON vs. UHR) -0.01 .9755
Correlation in RISK-T
Thickness Left Lateral Occipital (CT difference RISK-NT vs. RISK-T) 0.35 .3161
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Table S2.3.2: Correlation between clusters with morphometric differences and COPER sum score
Cluster Correlation Coefficient Rho P
Correlation in UHR
Surface Area Left Orbitofrontal (CSA difference BS vs. UHR) -0.23 .1589
Surface Area Right Posterior Cingulate (CSA difference BS vs. UHR) 0.02 .8899
Surface Area Left Orbitofrontal (CSA difference CON vs. UHR) -0.17 .2900
Surface Area Left Lateral Occipital (CSA difference CON vs. UHR) -0.17 .2995
Surface Area Right Superior Parietal (CSA difference CON vs. UHR) -0.27 .1015
Correlation in RISK-T
Thickness Left Lateral Occipital (CT difference RISK-NT vs. RISK-T) -0.40 .2552
Correlation in RISK (BS and UHR)
Surface Area Left Orbitofrontal (CSA difference BS vs. UHR) 0.06 .5774
Surface Area Right Posterior Cingulate (CSA difference BS vs. UHR) 0.17 .1163
Surface Area Left Orbitofrontal (CSA difference CON vs. UHR) 0.07 .5194
Surface Area Left Lateral Occipital (CSA difference CON vs. UHR) -0.00 .9982
Surface Area Right Superior Parietal (CSA difference CON vs. UHR) -0.05 .6397
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Table S2.3.3: Correlation between clusters with morphometric differences and COGDIS sum score
Cluster Correlation Coefficient Rho P
Correlation in UHR
Surface Area Left Orbitofrontal (CSA difference BS vs. UHR) -0.31 .0542
Surface Area Right Posterior Cingulate (CSA difference BS vs. UHR) -0.09 .5765
Surface Area Left Orbitofrontal (CSA difference CON vs. UHR) -0.22 .1769
Surface Area Left Lateral Occipital (CSA difference CON vs. UHR) -0.25 .1263
Surface Area Right Superior Parietal (CSA difference CON vs. UHR) -0.18 .2726
Correlation in RISK-T
Thickness Left Lateral Occipital (CT difference RISK-NT vs. RISK-T) -0.26 .4697
Correlation in RISK (BS and UHR)
Surface Area Left Orbitofrontal (CSA difference BS vs. UHR) -0.03 .7930
Surface Area Right Posterior Cingulate (CSA difference BS vs. UHR) 0.08 .4511
Surface Area Left Orbitofrontal (CSA difference CON vs. UHR) -0.02 .8520
Surface Area Left Lateral Occipital (CSA difference CON vs. UHR) -0.02 .8239
Surface Area Right Superior Parietal (CSA difference CON vs. UHR) 0.02 .8512
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S2.4 Additional analysis: Morphological differences in BS subjects meeting COGDIS crite-
rion
Upon request of a reviewer, we additionally performed the analysis with a modified BS group. Specifically, we excluded
BS subjects (n=14) who only met the COPER criterion but not the COGDIS criterion. Hence, each BS subject in this
additional analysis fulfilled the COGDIS criterion (n=32) while the CON (n=34) and UHR (n=39) groups remained the
unchanged. As shown in Figure S2.4.1 and Table S2.4.1, the results did not differ substantially.



































BS vs. UHR CON vs. UHR CON vs. BS
Figure S2.4.1. Morphometric differences when BS subjects who fulfill COGDIS were compared to CON and UHR.
Colored highlights show areas of significant differences (cluster-wise threshold set at p < .05, two-tailed, Monte Carlo simulations); red
indicates greater values in the first group, while blue would show regions with greater values in the second group of the comparison.
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S2.5 Additional analysis: Group-by-age interaction CON vs. UHR volume
On demand of a reviewer, a group-by-age interaction analysis between CON and UHR groups was conducted. This anal-
ysis revealed a significantly different age slope in the left dorsolateral frontal cortex between these groups.












































































Figure S2.5.1. Group-by-age interaction in CON vs. UHR. Colored highlights show areas of significant different age slope
between groups (cluster-wise threshold set at p < .05, two-tailed, Monte Carlo simulations); red would indicate greater values in the
first group, while blue shows regions with greater values in the second group of the comparison. The scatter plot shows the different
slopes in this significant cluster for each group
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S2.6 Additional analysis: Whole-brain correlation analyses
As requested by a reviewer, the association with symptoms (COPER sum score, COGDIS sum score, SIPS positive score,
SIPS negative score) was tested among the whole RISK group (i. e. BS and UHR) and across the whole cortex.
S2.6.1 Correlation with COPER (sum score)
Figure S2.6.1. Correlation between surface area and COPER sum score. Colored highlights show areas of significant
correlations (cluster-wise threshold set at p < .05, two-tailed, Monte Carlo simulations); red indicates a positive correlation, while blue
would show regions with negative correaltions.
S2.6.2 Correlation with COGDIS (sum score)
No clusters with significant correlations between surface area and COGDIS sum score were found in RISK subjects (BS
and UHR groups together).
16
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S2.6.3 Correlation with positive Symptoms (SIPS positive score)
Figure S2.6.3a: Group-by-age interaction CON vs. UHR volume
Figure S2.6.3a. Correlation between surface area and SIPS positive score. Colored highlights show areas of significant
correlations (cluster-wise threshold set at p < .05, two-tailed, Monte Carlo simulations); red indicates a positive correlation, while blue
would show regions with negative correaltions.
The cluster shown in the upper panel (A) is overlapping with one of the significant clusters of group differences in BS
vs. UHR (see Figure 1 and Table 1). Hence, there is a chance that this correlation might evolve because of group
differences in surface area and SIPS positive score (one group with low values in both variables combined with the second
group presenting high values in both variables). In order to elucidate the associations between the positive symptoms and
surface area in each group, we additionally tested the correlation group-wise and plotted (Figure S2.6.3b) the results for
each group separately. As shown in Table S2.6.3b, the correlation is driven by BS subjects.
17
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Table S2.6.3b: Correlation left medial orbitofrontal and VMPFC
surface area with SIPS positive score
Group Correlation Coefficient Rho P
Correlation in RISK (BS and UHR) 0.37 .0005
Correlation within BS group 0.32 .0298
Correlation within UHR group 0.21 .1925
Figure S2.6.3b: Correlation with SIPS positive score
Figure S2.6.3b: Correlation between surface area and SIPS positive
score within the BS and UHR groups respectively.
S2.6.4 Correlation with negative Symptoms (SIPS negative score)
No clusters with significant correlations between surface area and SIPS negative score were found in RISK subjects (BS
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Characteristics of subjects assigned to three test groups.
CON BS UHR Statistics
(n=34) (n=46) (n=39) F,χ2,U p Cohen’s d
Age in years [m±sd] 21.76±3.73 22.7±4.03 21.79±4.71 F=0.6752 0.5111
-range 16−31 16−29 16−35
Sex male/female (%male) 16/18 (47%) 23/23 (50%) 25/14 (64%) χ2=2.5541 0.2789
Handedness r/a/l (%left) 27/3/4 (12%) 42/2/2 (4%) 36/0/3 (8%) χ2=5.2152 0.2659
Estimated IQ [m±sd] 112.13±13.68 105.91±11.49 107.25±14.34 F=2.3149 0.1034
COPER sum score [m±sd] NA 14.61±5.43 19.33±10.7 U=636.5 0.0216 -0.56
COGDIS sum score [m±sd] NA 11.76±6.45 14.67±8.67 U=711 0.1014
SIPS Positive score [m±sd] NA 4.67±2.93 10.67±3.89 U=170.5 <.001 -1.74
SIPS Negative score [m±sd] NA 11.24±5.85 13.59±5.79 U=689.5 0.0675
SIPS General [m±sd] NA 7.28±3.42 8.9±3.68 U=633.5 0.0197 -0.46
SIPS Disorganization [m±sd] NA 2.93±1.87 5.08±2.58 U=454 <.001 -0.95
GAF [m±sd] NA 57.98±16.4 50.33±12.68 U=1121 0.0087 0.52
Chlorpromazine [m±sd] NA 21.66±63.01 40.33±101.7 U=781 0.1706
Transition (3-year follow-up, mean = 12.2 months)
to F20 NA 3 (RISK-T) 7 (RISK-T)
to F23/BPD I NA 2 F23 1 F23/1 BPD
Abbreviations: CON, control group; BS, basic symptoms group; UHR, ultra-high risk group; m, mean; sd,
standard deviation; r, right; a, ambidextrous; l, left; COPER, cognitive-perceptive basic symptoms; COGDIS,
cognitive disturbances; SPIA, Schizophrenia Proneness Instrument Adult Version; SIPS, Structured Interview
for Psychosis-Risk Syndromes; GAF, global assessment of functioning; CPZ, chlorpromazine; F, ANOVA
F test; χ2, Chi-square test; U, Mann-Whitney U test; BPD, Bipolar I disorder; F23, Acute and transient
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